Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders

Seminars in Hematology

Volumn 37, Issue 1 SUPPL. 3, 2000, Pages 26-34

  Thomas, Deborah A ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; THALIDOMIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL;

EID: 0034019104     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(00)90080-5     Document Type: Article

References (35)

1. JE Cortes HM Kantarjian Acute lymphocytic leukemia: A comprehensive review with emphasis of biology and therapy Cancer 76 1995 2393 2417
2. EH Estey H Kantarjian MJ Keating Therapy for acure myeloid leukemia R Hoffman E Benz Jr S Shattil Hematology: Basic Principles and Practice 1994 Churchill Livingstone New York, NY 1014 1028
3. DA Thomas H Kantarjian TL Smith Primary refractory and relapsed adult acute lymphoblastic leukemia: Characteristics, treatment results, and prognosis with salvage therapy Cancer 86 1999 1216 1230
4. M Beran E Estey S O'Brien Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia J Clin Oncol 17 1999 2819 2830
5. EH Estey HM Kantarjian S O'Brien High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF) Cytokines Mol Ther 1 1995 21 28
6. S Faderl M Talpaz Z Estrov The biology of chronic myeloid leukemia N Engl J Med 341 1999 164 172
7. CL Sawyers Chronic myeloid leukemia N Engl J Med 17 1999 1330 1340
8. HM Kantarjian M Talpaz S O'Brien Chronic myelogenous leukemia—Progress at the M.D. Anderson Cancer Center over the past two decades and future directions: First Emil J Freireich Award Lecture Clin Cancer Res 3 1997 2723 2733
9. VA Morrison Chronic leukemias CA Cancer J Clin 44 1994 353 377
10. S Faderl HM Kantarjian M Talpaz Chronic myelogenous leukemia: Update on biology and treatment Oncology 13 1999 169 180
11. JJ Michiels J Kutti P Stark Diagnosis, pathogenesis, and treatment of myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis Neth J Med 54 1999 46 62
12. G Barosi Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines J Clin Oncol 17 1999 2954 2970
13. J Folkman Tumor angiogenesis: Therapeutic implications N Engl J Med 285 1971 1182 1186
14. J Folkman Angiogenesis in cancer, vascular, rheumatoid and other diseases Nat Med 1 1995 27 31
15. AR Perez-Atayde SE Sallan U Tedrow Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia Am J Pathol 150 1997 815 821
16. D Ribatti B Nico A Vacca Do mast cells help to induce angiogenesis in B-cell non-Hodgkin lymphomas? Br J Cancer 77 1998 1900 1906
17. D Ribatti A Vacca B Nico Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma Br J Cancer 79 1999 451 455
18. A Vacca M Di Loreto D Ribatti Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44 Am J Hematol 50 1995 9 14
19. A Vacca D Ribatti M Presta Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma Blood 93 1999 3064 3073
20. A Vacca D Ribatti L Roncali Bone marrow angiogenesis and progression in multiple myeloma Br J Haematol 87 1994 503 508
21. N Munshi CS Wilson J Penn Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies Blood 92 suppl 1 1998 98a abstr
22. T Kanbayashi T Shimizu Y Takahashi Thalidomide increases both REM and stage 3–4 sleep in human adults: A preliminary study Sleep 22 1999 113 115
23. RJ D'Amato MS Loughnan E Flynn Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 1994 4082 4085
24. EP Sampaio EN Sarno R Galilly Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes J Exp Med 173 1991 699 703
25. G Ghigliotti T Repetto A Farris Thalidomide: Treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus J Am Acad Dermatol 28 1993 271 272
26. JM Jacobson JS Greenspan J Spritzler Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection N Engl J Med 336 1997 1487 1493
27. S Kulkarni R Powles J Mehta Thalidomide in GVHD—Is anti-GVHD effect separable from the antiangiogenesis? Blood 92 suppl 1 1998 344b abstr
28. J Sheskin Thalidomide in the treatment of lepra reactions Clin Pharmacol Ther 6 1965 303 306
29. GB Vogelsang AD Hess GW Santos Thalidomide for treatment of graft-versus-host disease Bone Mar row Transplant 3 1988 393 398
30. SJ Hatfill ED Fester DP de Beer Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites Leuk Res 15 1991 129 136
31. H Grabstald R Golbey Clinical experiences with thalidomide in patients with cancer Clin Pharmacol Ther 6 1965 298 302
32. P Politi G Reboredo M Losso Phase I trial of thalidomide (T) in AIDS-related Kaposi sarcoma (KS) Proc Am Soc Clin Oncol 17 1998 41a (abstr)
33. T Eisen C Boshoff MM Vaughan Antiangiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancers with thalidomide: A phase II study Proc Am Soc Clin Oncol 17 1998 441a (abstr)
34. B Barlogie R Desikan N Munshi Single course D.T. PACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma (MM) Blood 92 suppl 1 1998 273b abstr
35. S Singhal J Mehta P Eddlemon Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM) Blood 92 suppl 1 1998 318a abstr